Maqui (Aristotelia chilensis)

Maqui berry (Aristotelia chilensis) is a Chilean fruit exceptionally rich in delphinidins, a class of monomeric anthocyanins that exert potent antioxidant effects by scavenging reactive oxygen species and chelating pro-oxidant metal ions. These polyphenols also demonstrate antihemolytic and preliminary anticancer activity by modulating oxidative stress pathways at the cellular level.

Origin & History

Maqui (Aristotelia chilensis) is an evergreen shrub native to the temperate rainforests of southern Chile and Argentina. Its dark purple berries are harvested primarily from the regions of La Araucanía and Los Ríos in Chile. These berries are processed using aqueous and organic solvent methods to extract polyphenolic compounds.

Historical & Cultural Context

Although specific historical uses are not detailed, the sourcing of berries from Chilean forests, such as the Mulchen and Bio-Bio regions, implies a traditional significance in local practices. However, the exact cultural applications remain unspecified.

Health Benefits

• Antioxidant properties due to high monomeric anthocyanin content, as measured by ORAC assays (Preliminary evidence).
• Antihemolytic activity observed in vitro (Preliminary evidence).
• Potential to reduce cell viability in Ishikawa endometrial cancer cells using hydroethanolic extracts (Preliminary evidence).
• High total polyphenol content which may contribute to general health (Preliminary evidence).
• Temperature-enhanced polyphenol diffusion, potentially increasing antioxidant capacity (Preliminary evidence).

How It Works

Maqui berry's primary bioactives, delphinidin-3-sambubioside and delphinidin-3,5-diglucoside, neutralize free radicals via electron donation and inhibit lipid peroxidation by chelating ferrous ions that catalyze the Fenton reaction. In vitro evidence suggests these anthocyanins may downregulate pro-survival signaling pathways such as PI3K/Akt in endometrial cancer cell lines, reducing cell viability in a dose-dependent manner when delivered as hydroethanolic extracts. Antihemolytic effects are attributed to membrane stabilization in erythrocytes, likely through direct interaction of polyphenols with phospholipid bilayers and inhibition of oxidative hemolysis.

Scientific Research

There are currently no human clinical trials, RCTs, or meta-analyses available for maqui (Aristotelia chilensis). The research is focused on extraction optimization and in vitro studies, lacking specific study designs or PMIDs.

Clinical Summary

Current evidence for maqui berry is largely preclinical, derived from in vitro ORAC assays and cell-culture models rather than robust human clinical trials. Antioxidant capacity has been quantified using standardized ORAC methodology, where maqui extracts consistently outperform many other berry species, though ORAC scores do not directly translate to in vivo bioavailability or efficacy. Antihemolytic activity has been demonstrated in red blood cell models exposed to oxidative stressors, but human trial data on dosage, pharmacokinetics, and clinical endpoints remain absent or extremely limited. The anticancer findings in Ishikawa endometrial cancer cells are preliminary and require validation in animal models and controlled human studies before any therapeutic conclusions can be drawn.

Nutritional Profile

Maqui berry (Aristotelia chilensis) is a nutrient-dense dark purple berry with the following documented composition per 100g fresh weight where available: Macronutrients are limited in published data, but the berry is low in calories with moderate carbohydrate content typical of small berries. Key bioactive compounds include: Anthocyanins (primary bioactives) at approximately 138–212 mg per 100g fresh weight, dominated by delphinidins (delphinidin-3-sambubioside-5-glucoside and delphinidin-3,5-diglucoside accounting for ~70–75% of total anthocyanins) and cyanidin derivatives (~25–30%); these are among the highest anthocyanin concentrations recorded in any known fruit. Total polyphenol content measured at approximately 27–37 mg gallic acid equivalents (GAE) per gram dry weight. ORAC (Oxygen Radical Absorbance Capacity) values reported at 27,600–29,000 µmol TE per 100g, significantly exceeding blueberry and açaí. Flavonoids including quercetin and rutin are present in moderate quantities. Ellagic acid and other ellagitannins have been identified. Vitamin C is present at moderate concentrations (~10–20 mg per 100g, though precise values are limited in literature). Minerals including potassium, calcium, and magnesium are present at trace-to-moderate levels consistent with small Andean berries; precise mineral panels are poorly characterized in peer-reviewed sources to date. Fiber content is estimated at 2–4g per 100g fresh weight based on comparable berry species. Bioavailability notes: Delphinidin-based anthocyanins generally exhibit lower oral bioavailability than cyanidin forms due to structural instability at physiological pH; however, colonic microbiota metabolites (phenolic acids such as protocatechuic acid) may contribute to systemic effects. Commercial freeze-dried maqui powder concentrates these values approximately 8–10 fold per gram.

Preparation & Dosage

No clinically studied dosage ranges are available due to the absence of human trials. The extraction processes are optimized for bioactive yield, but therapeutic dosing is unspecified. Consult a healthcare provider before starting any new supplement.

Synergy & Pairings

Acai, Blueberry, Pomegranate, Green Tea, Resveratrol

Safety & Interactions

Maqui berry consumed as a food or juice is generally considered safe at dietary amounts, though standardized supplement doses have not been established or evaluated in formal safety trials. Due to its anthocyanin content and potential antioxidant interactions, high-dose maqui supplements could theoretically interfere with chemotherapy agents that rely on oxidative mechanisms, and caution is warranted in oncology patients. No well-documented drug interactions have been confirmed in clinical studies, but polyphenol-rich extracts may modestly influence CYP450 enzyme activity, warranting caution with narrow-therapeutic-index drugs. Safety data during pregnancy and lactation are insufficient, so use of concentrated maqui supplements should be avoided in these populations until further research is available.